Clinical Trials Logo

CDNKN2A Loss Defined clinical trials

View clinical trials related to CDNKN2A Loss Defined.

Filter by:
  • None
  • Page 1

NCT ID: NCT02202200 Recruiting - Clinical trials for Melanoma BRAF V600E/K Mutated

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

OPTIMUM
Start date: May 2014
Phase: Phase 1/Phase 2
Study type: Interventional

An open label multicentre, phase I-II study with tumour molecular pharmacodynamics (MPD) evaluation and pharmacokinetics of PD-0332991 added to vemurafenib in patients suffering metastatic melanoma with BR. The main objective is to establish the Maximum Tolerated Dose (MTD) of PD-0332991 when added to standard vemurafenib therapy (960 mg BID). The estimated MTD is defined as the dose of PD-0332991 combined with vemurafenib that will be associated with a prespecified proportion of patients experiencing a Dose-Limiting Toxicity (DLT), ie, 1/3.